Network-targeted combination therapy: A new concept in cancer treatment

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 425-433

  Araujo, Robyn P ^a   Doran, Connemara ^a   Liotta, Lance A ^a   Petricoin, Emanuel F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ARTICLE; BIOCHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL CYCLE; DRUG TARGETING; HUMAN; INDIVIDUALIZATION; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL COMPUTING; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MULTIMODALITY CANCER THERAPY; PATIENT CARE; POSITIVE FEEDBACK; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; THEORETICAL MODEL;

EID: 13344294297     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.004     Document Type: Review

References (31)

1. M. Veit New strategies for drug development Berl. Munch. Tierarztl. Wochenschr. 117 2004 276-287
2. S. Marchini et al. New molecules and strategies in the field of anticancer agents Curr. Med. Chem. Anti-Canc. Agents 4 2004 247-262
3. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309-315
4. A. Awada et al. New anticancer agents and therapeutic strategies in development for solid cancers: A clinical perspective Expert Rev. Anticancer Ther. 4 2004 53-60
5. S. Shankar R.K. Srivastava Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: Mechanisms and clinical implications Drug Resist. Updat. 7 2004 139-156
6. P.M. Harari S. Huang Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results? Int. J. Radiat. Oncol. Biol. Phys. 58 2004 976-983
7. S.B. Noonberg C.C. Benz Tyrosine kinase inhibitor targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents Drugs 59 2000 753-767
8. D. Raben et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Semin. Oncol. 29 1 Suppl. 4 2002 37-46
9. F. Koizumi et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor Gefitinib ("Iressa") and the DNA Topoisomerase I inhibitor CPT-11 (Irinotecan) in human colorectal cancer cells Int. J. Cancer 108 2004 464-472
10. C.J. Langer Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC Int. J. Radiat. Oncol. Biol. Phys. 58 2004 991-1002
11. G. Tortora et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity Clin. Cancer Res. 7 2001 4156-4163
12. M. Ranson ZD1839 (Iressa™): For more than just non-small cell lung cancer Oncologist 7 Suppl. 4 2002 16-24
13. G.P. Dasmahapatra et al. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines Clin. Cancer Res. 10 2004 5242-5252
14. Araujo, R.P. et al. A mathematical model of combination therapy using the EGFR signaling network. Biosystems (in press)
15. B.N. Kholodenko Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades Eur. J. Biochem. 267 2000 1583-1588
16. V. Spirin L.A. Mirny Protein complexes and functional modules in molecular networks Proc. Natl. Acad. Sci. USA 100 2003 12123-12128
17. C. Herrmann et al. Connectivity distribution of spatial networks Phys. Rev. E 68 2 Pt. 2 2003 1-6
18. J.J. Tyson et al. Sniffers, buzzers, toggles and blinkers: Dynamics or regulatory and signaling pathways in the cell Curr. Opin. Cell Biol. 15 2003 221-231
19. C.Y. Huang and J.E. Ferrell Ultrasenstivity in the mitogen-activated protein kinase cascade Proc. Natl. Acad. Sci. USA 93 1996 10078-10083
20. N. Bluthgen and H. Herzel How robust are switches in intracellular signaling cascades? J. Theor. Biol. 225 2003 293-300
21. R.L. Bar-Or et al. Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study Proc. Natl. Acad. Sci. USA 97 2000 11250-11255
22. B.N. Kholodenko et al. Quantification of short term signaling by the epidermal growth factor receptor J. Biol. Chem. 274 1999 30169-30181
23. A. Felici et al. Dosing strategies for anticancer drugs: The good, the bad and the body-surface area Eur. J. Cancer 38 2002 1677-1684
24. M. Vulfovich N. Saba Molecular biological design of novel antineoplastic therapies Expert Opin. Investig. Drugs 13 2004 577-607
25. J.G. Paez et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497-1500
26. T.J. Lynch et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129-2139
27. M.C. Heinrich et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J. Clin. Oncol. 21 2003 4342-4349
28. A. Duensing et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) Oncogene 23 2004 3999-4006
29. M.C. Heinrich et al. PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708-710
30. H. Davies et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949-954
31. C.L. Artega J. Baselga Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice Clin. Cancer Res. 9 2003 1579-1589